Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
The Journal of Family Practice
|
April 20, 2010
Transforming strategies for the prevention of chronic HBV and HCV infections
John W Ward, Dale J Hu, Miriam J Alter, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 26, 2013
Recommendations for the management of hepatitis C virus infection among people who inject drugs
Geert Robaeys, Jason Grebely, Stefan Mauss, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
May 19, 2017
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse
François M J Lamoury, Angelica Soker, Danica Martinez, et al.
The International Journal on Drug Policy
|
January 11, 2016
Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden
Jason Grebely, Geert Robaeys, Philip Bruggmann, et al.
The International Journal on Drug Policy
|
August 19, 2015
Recommendations for the management of hepatitis C virus infection among people who inject drugs
Jason Grebely, Geert Robaeys, Philip Bruggmann, et al.
The International Journal on Drug Policy
|
February 6, 2016
Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection
Jason Grebely, Geert Robaeys, Philip Bruggmann, et al.
The Lancet. Gastroenterology & Hepatology
|
July 31, 2020
Global hepatitis C elimination: an investment framework
Alisa Pedrana, Jessica Howell, Nick Scott, et al.
The International Journal on Drug Policy
|
June 19, 2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
Jason Grebely, Olav Dalgard, Evan B Cunningham, et al.
BMC Infectious Diseases
|
June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
Evan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 22, 2019
Innovative strategies for the elimination of viral hepatitis at a national level: A country case series
Sophia E Schröeder, Alisa Pedrana, Nick Scott, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
The Journal of Family Practice
|
April 20, 2010
Transforming strategies for the prevention of chronic HBV and HCV infections
John W Ward, Dale J Hu, Miriam J Alter, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 26, 2013
Recommendations for the management of hepatitis C virus infection among people who inject drugs
Geert Robaeys, Jason Grebely, Stefan Mauss, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
May 19, 2017
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse
François M J Lamoury, Angelica Soker, Danica Martinez, et al.
The International Journal on Drug Policy
|
January 11, 2016
Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden
Jason Grebely, Geert Robaeys, Philip Bruggmann, et al.
The International Journal on Drug Policy
|
August 19, 2015
Recommendations for the management of hepatitis C virus infection among people who inject drugs
Jason Grebely, Geert Robaeys, Philip Bruggmann, et al.
The International Journal on Drug Policy
|
February 6, 2016
Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection
Jason Grebely, Geert Robaeys, Philip Bruggmann, et al.
The Lancet. Gastroenterology & Hepatology
|
July 31, 2020
Global hepatitis C elimination: an investment framework
Alisa Pedrana, Jessica Howell, Nick Scott, et al.
The International Journal on Drug Policy
|
June 19, 2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
Jason Grebely, Olav Dalgard, Evan B Cunningham, et al.
BMC Infectious Diseases
|
June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
Evan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 22, 2019
Innovative strategies for the elimination of viral hepatitis at a national level: A country case series
Sophia E Schröeder, Alisa Pedrana, Nick Scott, et al.
Page
of 5